Anzeige
Meldung des Tages: China verknappt Germanium – und diese Aktie könnte davon erheblich profitieren

Azitra News

Aktie
WKN:  ISIN:  US05479L3024 US-Symbol:  AZTR
0,2345 $
+0,00 $
0,00%
0,20327 € 02:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
574,55 Tsd. €
Streubesitz
89,58%
KGV
-
Index-Zuordnung
-

Azitra News

19.03.26 - PR Newswire
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million PR Newswire
13.03.26 - PR Newswire
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
Azitra Receives Notice of Non-​Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement PR Newswire
05.03.26 - PR Newswire
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders PR Newswire
27.02.26 - PR Newswire
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates PR Newswire
24.02.26 - PR Newswire
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-​Associated Skin Rash PR Newswire
19.02.26 - PR Newswire
Azitra, Inc. to Present at BIO Investment & Growth Summit
Azitra, Inc. to Present at BIO Investment & Growth Summit PR Newswire
06.02.26 - PR Newswire
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting PR Newswire
07.01.26 - PR Newswire
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference PR Newswire
17.12.25 - PR Newswire
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American PR Newswire
24.11.25 - PR Newswire
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules PR Newswire
12.11.25 - PR Newswire
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates PR Newswire
07.11.25 - PR Newswire
Azitra, Inc. Addresses False Report Regarding Sale of Securities
Azitra, Inc. Addresses False Report Regarding Sale of Securities PR Newswire
20.10.25 - PR Newswire
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris PR Newswire
03.10.25 - PR Newswire
Azitra Receives Notice of Non-Compliance from NYSE American
Azitra Receives Notice of Non-​Compliance from NYSE American PR Newswire
04.09.25 - PR Newswire
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
27.08.25 - PR Newswire
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-​Associated Rash PR Newswire
11.08.25 - PR Newswire
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates PR Newswire
11.08.25 - PR Newswire
Azitra, Inc. Announces Reverse Stock Split
Azitra, Inc. Announces Reverse Stock Split PR Newswire
17.06.25 - PR Newswire
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome PR Newswire
14.05.25 - PR Newswire
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-​Associated Rash PR Newswire

Newssuche

Videos

newspaper
01.04.26
Saisonalitäten: DAS machst Du falsch!
Viele Trader landen irgendwann bei Saisonalitäten, ziehen diesen stark fundamental basierten Ansatz ... Mehr »